MP 196

Drug Profile

MP 196

Alternative Names: Anti IL23/P19 monoclonal antibody - OSE Immunotherapeutics; MP-196

Latest Information Update: 02 Jun 2016

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Effimune
  • Developer OSE Immunotherapeutics
  • Class Monoclonal antibodies
  • Mechanism of Action Interleukin 23 inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Preclinical Autoimmune disorders

Most Recent Events

  • 31 May 2016 Effimune has merged with OSE Pharma to form OSE Immunotherapeutics
  • 03 Mar 2016 Preclinical trials in Autoimmune disorders in France (Parenteral) before March 2016
  • 03 Mar 2016 Effimune has patent protection for antibodies directed against p19 subunit of human IL-23 in Europe (Effimune pipeline, March 2016)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top